ReviewCNS & neurological disorders drug targets2011
Anti-cocaine vaccine based on coupling a cocaine analog to a disrupted adenovirus.
Review in CNS & neurological disorders drug targets, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- COT-TT vaccine attenuates induction and expression of cocaine-induced behavioral sensitization in rats: a dose-response study.Frontiers in psychiatry · 2025Article
- COT-TT vaccine attenuates cocaine-seeking and cocaine-conditioned place preference in rats.Human vaccines & immunotherapeutics · 2024Article
- Role of homologous recombination/recombineering on human adenovirus genome engineering: Not the only but the most competent solution.Engineering microbiology · 2024Review
- PPL-103: A mixed opioid partial agonist with desirable anti-cocaine properties.Progress in neuro-psychopharmacology & biological psychiatry · 2022Article
- Calix[Journal of advanced research · 2022Article
- New Drugs, Old Targets: Tweaking the Dopamine System to Treat Psychostimulant Use Disorders.Annual review of pharmacology and toxicology · 2021Article
- The neurobiology of addiction.Annals of the New York Academy of Sciences · 2019Article
- Investigations into the efficacy of multi-component cocaine vaccines.Bioorganic & medicinal chemistry letters · 2018Article
- Efficient Syntheses of Cocaine Vaccines and TheirACS medicinal chemistry letters · 2018Article
- Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse.PloS one · 2018Article
- A bioconjugate leveraging xenoreactive antibodies to alleviate cocaine-induced behavior.Chemical communications (Cambridge, England) · 2017Article
- Biologics to treat substance use disorders: Current status and new directions.Human vaccines & immunotherapeutics · 2016Review
- The Carbomer-Lecithin Adjuvant Adjuplex Has Potent Immunoactivating Properties and Elicits Protective Adaptive Immunity against Influenza Virus Challenge in Mice.Clinical and vaccine immunology : CVI · 2015Article
- Flagellin as carrier and adjuvant in cocaine vaccine development.Molecular pharmaceutics · 2015Article
- Adjuvants may reduce in vivo transfection levels for DNA vaccination in mice leading to reduced antigen-specific CD8+ T cell responses.Human vaccines & immunotherapeutics · 2015Article
- Vaccines against drugs of abuse: where are we now?Therapeutic advances in vaccines · 2014Review
- Adenovirus: the first effective in vivo gene delivery vector.Human gene therapy · 2014Review
- Probing the effects of hapten stability on cocaine vaccine immunogenicity.Molecular pharmaceutics · 2013Article
- Adenovirus capsid-based anti-cocaine vaccine prevents cocaine from binding to the nonhuman primate CNS dopamine transporter.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Article
- Probing active cocaine vaccination performance through catalytic and noncatalytic hapten design.Journal of medicinal chemistry · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
The challenge in developing an anti-cocaine vaccine is that cocaine is a small molecule, invisible to the immune system. Leveraging the knowledge that adenovirus (Ad) capsid proteins are highly immunogenic in humans, we hypothesized that linking a cocaine hapten to Ad capsid proteins would elicit high-affinity, high-titer antibodies against cocaine, sufficient to sequester systemically administered cocaine and prevent access to the brain, thus suppressing cocaine-induced behaviors. Based on these concepts, we developed dAd5GNE, a disrupted E1-E3- serotype 5 Ad with GNE, a stable cocaine analog, covalently linked to the Ad capsid proteins. In pre-clinical studies, dAd5GNE evoked persistent, high titer, high affinity IgG anti-cocaine antibodies, and was highly effective in blocking cocaine-induced hyperactivity and cocaine self-administration behavior in rats. Future studies will be designed to expand the efficacy studies, carry out relevant toxicology studies, and test dAd5GNE in human cocaine addicts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.